Alteon halts hypertension trial

Alteon of Parsippany, New Jersey, has halted its Phase IIb trial of alagebrium after an independent review board concluded it did not demonstrate sufficient efficacy against uncontrolled systolic hypertension. The company also announced that it had submitted preclinical toxicity data on alagebrium to two divisions of the FDA supporting its view that liver alterations previously observed in rats, which led to a voluntary suspension of enrolling new patients into its clinical trials, were related to the male rat metabolism and not to genotoxic pathways.

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.